- Tumour mutation burden is a dispensable test in endometrial carcinoma patients whose molecular classification is knownJiang, H.; Chen, S.; Wang, Q.; Deng, Y.; Wang, S.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
- Intratumoral heterogeneity as a predictive biomarker in immunotherapy for advanced non-small cell lung cancer.Xiao, HaiPing; Chen, Kai; Zheng, Yating; Huang, MengliAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- ZFHX4 mutation as a novel predictive biomarker for immune checkpoint blockade in non-small cell lung cancer.Shen, Peng; Zeng, Di; Lin, Zhenzi; Lin, Pei; Luo, Mingyang; Zhao, Lele; Chai, Huizi; Huang, Lingli; Xiao, MingzheAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
会议论文
Tumor mutation burden is a predictive biomarker for survival to patients with ovarian carcinoma
11阅读
